Pfizer (NYSE:PFE) yield tops 7% after stock falls on China GLP-1 news

Pfizer Inc traded lower Tuesday afternoon, trailing the main indexes again and raising fresh questions around the stock’s dividend. The New York Stock Exchange was open for normal trading hours. Its 2026 holiday calendar lists July 3 as the next full-day closure for Independence Day.

30 June 2026

Abivax stock jumps as safety denominator eases obefazimod cancer worry

Abivax SA rose sharply in Paris on Tuesday after late Monday data gave investors a cleaner way to judge cancer risk in its ulcerative colitis drug programme. Euronext Paris was open for a regular session, with June 30 listed as a 0900-1730 CEST trading day.

30 June 2026

EPA:ABVX·Health News·Pharmaceuticals·Stock Market

Pfizer (NYSE:PFE) trails S&P 500 as China GLP-1 watch puts yield in focus

Pfizer Inc. ticked up on Monday, rising after a move in China increased reimbursement for its GLP-1 offering, giving it another inroad into the market. Shares added 0.4% to $24.37 late in New York trading, but trailed a broader rally. The S&P 500 ended up 1.18% at 7,440.43, and the Nasdaq Composite jumped 2.07%.

30 June 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Universe Pharmaceuticals (NASDAQ:UPC) pop puts $10.75M patent deal and float in focus

Universe Pharmaceuticals INC shares surged in late Monday trading on a new patent deal, but what stood out for investors was the big share count jump. The China-based specialty pharma said it would issue 4,376,552 Class A shares to Best Praise International. StockAnalysis listed just 651,310 shares outstanding toward session end.

29 June 2026

Nasdaq·NASDAQ:UPC·Pharmaceuticals·Stock Market

Moderna (NASDAQ:MRNA) surge puts stock above most analyst targets ahead of FDA review

Moderna, Inc. heads into Monday’s U.S. session with its shares now outpacing most analyst targets, leaving the main story a stock issue instead of a scientific one. The stock traded at $67.63 in premarket at 7:01 a.m. EDT, up 0.54%, after jumping 12.59% to $67.27 on Friday. Volume hit 14.46 million shares Friday, 203% of the 65-day average.

29 June 2026

NASDAQ:MRNA·Pharmaceuticals·Stock Market

Eli Lilly and Company (NYSE:LLY) stock nears Cantor target after $76 billion Friday pop

At 05:01 EDT, the New York Stock Exchange cash session had not opened. NYSE lists a 9:30 a.m. to 4:00 p.m. ET core session, and its 2026 holiday list shows the next full U.S. market closure is July 3 for Independence Day observed.

29 June 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly (NYSE:LLY) gains $76 billion in one day as Jaypirca headlines land

Eli Lilly and Company closed at $1,208.12 on Friday, up $80.43. Markets in U.S. cash equities were closed Saturday, leaving Friday as the last pricing. About 7.73 million shares traded, coming in at roughly 2.5 times the average volume listed on Google Finance.

27 June 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly (NYSE:LLY) move lifts healthcare ETF on Medicare GLP-1 signal

Eli Lilly and Company jumped 6.5% to $1,200.98 by 1:46 p.m. EDT Friday, tacking on about $65.7 billion in market cap. Shares hovered close to the session’s high of $1,208.18. The stock was at 42.7 times earnings, with 3.6 million shares traded.

26 June 2026

ETFs·NYSE:LLY·Pharmaceuticals·Stock Market

Shuttle Pharmaceuticals (NASDAQ:SHPH) surges; Dogecoin miner news sends volume up 70x

Shuttle Pharmaceuticals Holdings Inc surged Friday as United Dogecoin, its unit, said it picked up its first Dogecoin miners and locked in a hydroelectric data centre site. The former drug developer saw sharp trading and became one of the busiest micro-cap names of the session.

26 June 2026

Cryptocurrency·NASDAQ:SHPH·Pharmaceuticals·Stock Market

Pfizer (NYSE:PFE): 7% yield in focus after FDA clears Ibrance but stock action mixed

Pfizer Inc. opens Thursday carrying a clearer income pitch, but growth looks shaky. Shares have slid, sending the dividend yield above 7%. The company scored an FDA win for Ibrance, its established breast cancer drug. But sigvotatug vedotin, a lung cancer antibody-drug conjugate from the Seagen deal, failed in late-stage testing.

25 June 2026

NYSE:PFE·Pharmaceuticals

Novo Nordisk (CPH:NOVO-B) gains as South Africa copycat order tops Ozempic, Wegovy local sales

Novo Nordisk’s B shares jumped 2.6% to 307.75 Danish crowns on Tuesday. The stock is up 5.1% since Friday’s close and has gained 9.9% over three sessions. The OMXC25 index in Copenhagen fell 0.07%.

24 June 2026

NYSE:CVS·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Pfizer Shares Fall After Lung-Cancer Setback Hits $43 Billion Seagen Deal

Pfizer Inc. shares fell on Tuesday. The company said a key lung cancer drug from its Seagen unit didn’t hit the main endpoint in a late-stage study. That’s another setback for Pfizer as it tries to spark growth again after its COVID-era products.

23 June 2026

NYSE:PFE·Pharmaceuticals·Stock Market

AbbVie grabs Apogee in $10.9 billion deal as buyouts speed up

AbbVie said Monday it will buy Apogee Therapeutics for $10.9 billion in cash, picking up a late-stage eczema drug in what would be its biggest deal in over five years. The $135.11 per share offer is about 49% over Apogee’s June 18 close. Both companies’ boards signed off, aiming to wrap up the deal in the third quarter.

22 June 2026

NASDAQ:APGE·NYSE:ABBV·Pharmaceuticals·Stock Market

AbbVie moves to acquire Apogee in $10.9 billion bet on immunology

AbbVie said Monday it’s buying Apogee Therapeutics for $10.9 billion in cash, making this its largest deal since 2019. The company is looking to strengthen its immunology pipeline with Apogee’s long-acting immune-disease drugs. AbbVie and Apogee put out a joint release on the agreement, according to a securities filing. They expect the deal to close in the third quarter of 2026.

22 June 2026

Biotechnology·NYSE:ABBV·Pharmaceuticals

Pfizer starts week on the back foot after CFO leaves, outlook for 2026 still stands

Pfizer Inc. shares slid again after its CFO said he’ll step down in August. The stock closed at $25.21, losing 2.7% on Thursday before the Juneteenth holiday and the weekend.

21 June 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Pfizer Stock Falls as CFO Dave Denton Exit Revives Questions on Growth Plan

Pfizer shares dip after CFO departure raises new questions about 2026 outlook

Pfizer dropped 2.7% to $25.21 Thursday, closing out a short week lower after its CFO said he is leaving. The news raised questions about Pfizer’s 2026 outlook and its post-pandemic turnaround. U.S. markets shut Friday for Juneteenth.

19 June 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Novo Nordisk Shares Rise As Ozempic Study Shows 15% Weight Loss In Older Adults

Novo Nordisk Shares Climb with OMXC25 as Healthcare Stocks Pull Higher

Novo Nordisk’s B shares traded in Copenhagen climbed roughly 5% Friday late morning. It was a strong move for Denmark’s top healthcare stock, giving a boost to the local index.

19 June 2026

NASDAQ:NVO·Pharmaceuticals·Stock Market

Pfizer Stock Falls as CFO Dave Denton Exit Revives Questions on Growth Plan

Pfizer shares dropped on Thursday after the drugmaker said finance chief Dave Denton would leave in August, a management change that hit a stock already being judged on a long and expensive growth rebuild.

18 June 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Pfizer trades up with Rigel’s Veppanu deal done

Pfizer Inc. shares ticked up Tuesday after Rigel Pharmaceuticals announced it has finalized a licensing deal for Veppanu, the breast-cancer treatment Arvinas and Pfizer developed together. The move offered a small bit of news in cancer drugs for investors. Broader U.S. indexes finished the session mixed.

17 June 2026

NASDAQ:ARVN·NASDAQ:RIGL·NYSE:PFE·Pfizer·Pharmaceuticals·Stock Market

AtaiBeckley climbs after kicking off Phase 3 for BPL-003 in depression

AtaiBeckley Inc. jumped 7.8% to $4.14 on Tuesday. Chief Executive Srinivas Rao said the company’s lead depression drug, BPL-003, advanced into Phase 3 trials. ATAI shares on Nasdaq moved between $3.83 and $4.34. Volume was close to 10 million shares.

16 June 2026

NASDAQ:ATAI·Pharmaceuticals